RU2012134637A - Ингибиторы рецепторных тирозинкиназ (rtk) и способы их применения - Google Patents
Ингибиторы рецепторных тирозинкиназ (rtk) и способы их применения Download PDFInfo
- Publication number
- RU2012134637A RU2012134637A RU2012134637/10A RU2012134637A RU2012134637A RU 2012134637 A RU2012134637 A RU 2012134637A RU 2012134637/10 A RU2012134637/10 A RU 2012134637/10A RU 2012134637 A RU2012134637 A RU 2012134637A RU 2012134637 A RU2012134637 A RU 2012134637A
- Authority
- RU
- Russia
- Prior art keywords
- molecule
- rtk
- binds
- monomer
- group
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims abstract 74
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims abstract 74
- 239000000178 monomer Substances 0.000 claims abstract 34
- 125000000539 amino acid group Chemical group 0.000 claims abstract 21
- 108091008794 FGF receptors Proteins 0.000 claims abstract 19
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 claims abstract 19
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 claims abstract 15
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 claims abstract 15
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 claims abstract 13
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 claims abstract 13
- 239000003446 ligand Substances 0.000 claims abstract 8
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims abstract 4
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims abstract 4
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 claims abstract 4
- 101710182387 Fibroblast growth factor receptor 4 Proteins 0.000 claims abstract 4
- 238000006471 dimerization reaction Methods 0.000 claims abstract 4
- 108091000080 Phosphotransferase Proteins 0.000 claims abstract 3
- 230000000694 effects Effects 0.000 claims abstract 3
- 102000020233 phosphotransferase Human genes 0.000 claims abstract 3
- 230000003197 catalytic effect Effects 0.000 claims abstract 2
- 230000001086 cytosolic effect Effects 0.000 claims abstract 2
- 239000002773 nucleotide Substances 0.000 claims abstract 2
- 125000003729 nucleotide group Chemical group 0.000 claims abstract 2
- 150000003384 small molecules Chemical class 0.000 claims 12
- 239000001132 aluminium potassium sulphate Substances 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 238000000034 method Methods 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000020084 Bone disease Diseases 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 239000000758 substrate Substances 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008723 Chondrodystrophy Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000008919 achondroplasia Diseases 0.000 claims 1
- 230000030609 dephosphorylation Effects 0.000 claims 1
- 238000006209 dephosphorylation reaction Methods 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Physical Education & Sports Medicine (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33595010P | 2010-01-14 | 2010-01-14 | |
| US61/335,950 | 2010-01-14 | ||
| PCT/US2011/021109 WO2011088196A2 (en) | 2010-01-14 | 2011-01-13 | Inhibitors of receptor tyrosine kinases (rtk) and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012134637A true RU2012134637A (ru) | 2014-02-20 |
Family
ID=44304965
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012134637/10A RU2012134637A (ru) | 2010-01-14 | 2011-01-13 | Ингибиторы рецепторных тирозинкиназ (rtk) и способы их применения |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20120328599A1 (enExample) |
| EP (1) | EP2523679A4 (enExample) |
| JP (1) | JP2013517282A (enExample) |
| KR (1) | KR20120130758A (enExample) |
| CN (1) | CN102762221A (enExample) |
| AU (1) | AU2011205297A1 (enExample) |
| BR (1) | BR112012016992A2 (enExample) |
| CA (1) | CA2786276A1 (enExample) |
| IL (1) | IL220206A0 (enExample) |
| IN (1) | IN2012DN05017A (enExample) |
| MX (1) | MX2012008222A (enExample) |
| RU (1) | RU2012134637A (enExample) |
| SG (1) | SG181850A1 (enExample) |
| WO (1) | WO2011088196A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103694351A (zh) | 2007-06-05 | 2014-04-02 | 耶鲁大学 | 受体酪氨酸激酶抑制剂及其使用方法 |
| EP3763740A1 (en) | 2011-01-26 | 2021-01-13 | Celldex Therapeutics, Inc. | Anti-kit antibodies and uses thereof |
| CN104812775B (zh) | 2012-07-25 | 2019-05-03 | 塞尔德克斯医疗公司 | 抗kit抗体及其用途 |
| US20150344855A1 (en) | 2013-01-16 | 2015-12-03 | INSERM (Institut National de la Santé et de la Recherche Médicale | A Soluble Fibroblast Growth Factor Receptor 3 (FGR3) Polypeptide For Use In The Prevention Or Treatment Of Skeletal Growth Retardation Disorders |
| US10300116B2 (en) | 2013-06-10 | 2019-05-28 | Ansun Biopharma, Inc. | Treatment for BK polyomavirus infection |
| PL3708583T3 (pl) | 2013-08-01 | 2022-06-06 | Five Prime Therapeutics, Inc. | Afukozylowane przeciwciała anty-fgfr2iiib |
| SG11201602069WA (en) | 2013-10-18 | 2016-04-28 | Eisai R&D Man Co Ltd | Pyrimidine fgfr4 inhibitors |
| WO2015179737A2 (en) | 2014-05-23 | 2015-11-26 | Kolltan Pharmaceuticals, Inc. | Treatment of eosinophil or mast cell related disorders |
| SG10201810057UA (en) | 2015-04-14 | 2018-12-28 | Eisai R&D Man Co Ltd | Crystalline fgfr4 inhibitor compound and uses thereof |
| JP7349787B2 (ja) | 2015-11-23 | 2023-09-25 | ファイヴ プライム セラピューティクス インク | 癌治療におけるｆｇｆｒ２阻害剤単独または免疫刺激剤との組み合わせ |
| US11357769B2 (en) | 2016-05-10 | 2022-06-14 | Eisai R&D Management Co., Ltd. | Drug combinations for reducing cell viability and/or cell proliferation |
| CN110129300B (zh) * | 2016-06-02 | 2021-08-03 | 天津科技大学 | 一种磷脂酶d |
| SI3481859T1 (sl) | 2016-07-07 | 2022-07-29 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Topni polipeptidi receptorja 3 fibroblastnega rastnega faktorja (SFGFR3) in njihove uporabe |
| JP7299842B2 (ja) | 2017-05-16 | 2023-06-28 | ファイヴ プライム セラピューティクス インク | がん治療における化学療法剤と組み合わせた抗ｆｇｆｒ２抗体 |
| JP2023538098A (ja) | 2020-08-21 | 2023-09-06 | ジェンザイム・コーポレーション | Ｆｇｆｒ３抗体および使用の方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8426396B2 (en) * | 2008-01-08 | 2013-04-23 | Shriners Hospitals For Children | Treatment for achondroplasia |
-
2011
- 2011-01-13 IN IN5017DEN2012 patent/IN2012DN05017A/en unknown
- 2011-01-13 MX MX2012008222A patent/MX2012008222A/es not_active Application Discontinuation
- 2011-01-13 AU AU2011205297A patent/AU2011205297A1/en not_active Abandoned
- 2011-01-13 JP JP2012549070A patent/JP2013517282A/ja not_active Withdrawn
- 2011-01-13 WO PCT/US2011/021109 patent/WO2011088196A2/en not_active Ceased
- 2011-01-13 BR BR112012016992A patent/BR112012016992A2/pt not_active IP Right Cessation
- 2011-01-13 RU RU2012134637/10A patent/RU2012134637A/ru not_active Application Discontinuation
- 2011-01-13 CN CN2011800061813A patent/CN102762221A/zh active Pending
- 2011-01-13 EP EP11733365.8A patent/EP2523679A4/en not_active Withdrawn
- 2011-01-13 CA CA2786276A patent/CA2786276A1/en not_active Abandoned
- 2011-01-13 KR KR1020127021221A patent/KR20120130758A/ko not_active Withdrawn
- 2011-01-13 US US13/519,837 patent/US20120328599A1/en not_active Abandoned
- 2011-01-13 SG SG2012045803A patent/SG181850A1/en unknown
-
2012
- 2012-06-06 IL IL220206A patent/IL220206A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011088196A3 (en) | 2011-11-17 |
| BR112012016992A2 (pt) | 2019-09-24 |
| EP2523679A2 (en) | 2012-11-21 |
| CA2786276A1 (en) | 2011-07-21 |
| SG181850A1 (en) | 2012-08-30 |
| IN2012DN05017A (enExample) | 2015-10-02 |
| EP2523679A4 (en) | 2013-07-24 |
| CN102762221A (zh) | 2012-10-31 |
| WO2011088196A2 (en) | 2011-07-21 |
| IL220206A0 (en) | 2012-07-31 |
| JP2013517282A (ja) | 2013-05-16 |
| KR20120130758A (ko) | 2012-12-03 |
| AU2011205297A1 (en) | 2012-06-28 |
| US20120328599A1 (en) | 2012-12-27 |
| MX2012008222A (es) | 2012-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012134637A (ru) | Ингибиторы рецепторных тирозинкиназ (rtk) и способы их применения | |
| Garner et al. | An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin | |
| de Vries et al. | Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis | |
| JP5855569B2 (ja) | 破骨細胞特異的抗原の生物学的活性を特異的にブロックする抗体 | |
| Meetze et al. | Neuregulin 1 expression is a predictive biomarker for response to AV-203, an ERBB3 inhibitory antibody, in human tumor models | |
| Zhang et al. | ERBB3/HER2 signaling promotes resistance to EGFR blockade in head and neck and colorectal cancer models | |
| Hassoun | Pulmonary arterial hypertension complicating connective tissue diseases | |
| KR20210003808A (ko) | 항-클라우딘 18.2 항체 및 이의 사용 | |
| Hegde et al. | A skin-depth analysis of integrins: role of the integrin network in health and disease | |
| JP2014524746A5 (enExample) | ||
| JP2014518615A5 (enExample) | ||
| US8044179B2 (en) | Methods and compositions for modulating tumor cell activity | |
| RU2010141584A (ru) | Антитело против csf-1r | |
| CN103747803A (zh) | 抗axl抗体及其用途 | |
| RS54762B1 (sr) | Solubilna humana st-2 antitela i eseji | |
| RU2013129450A (ru) | Способ лечения опухолей с применением vegf-специфических антагонистов | |
| TW201509431A (zh) | 人化ａｘｌ抗體類 | |
| WO2014012007A4 (en) | Rspo3 binding agents and uses thereof | |
| WO2009029591A3 (en) | Monoclonal antibody which binds met in formalin-fixed and paraffin-embedded tissues and related methods | |
| JP2007526908A5 (enExample) | ||
| BRPI0516975A (pt) | anticorpo ou seu fragmento de ligação a antìgeno, composição farmacêutica, imunoconjugado, hibridoma, anticorpo monoclonal, e, uso de um anticorpo ou seu fragmento de ligação a antìgeno | |
| KR102715157B1 (ko) | Il-17c에 대한 항체 | |
| Moody et al. | Antibody‐mediated neutralization of autocrine Gas6 inhibits the growth of pancreatic ductal adenocarcinoma tumors in vivo | |
| Samineni et al. | Impact of Shed/Soluble targets on the PK/PD of approved therapeutic monoclonal antibodies | |
| JP2012505227A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20140114 |